| Name | SK-575 |
| Description | SK-575 is a degradation agent targeting protein-hydrolyzed PARP1 chimera with anticancer and antitumor activity.SK-575 effectively inhibits the growth of cancer cells harboring BRCA1/2 mutations and selectively induces PARP1 degradation in cancer cells. |
| In vitro | In MDA-MB-436, Capan-1, and SW620 cells, SK-575 (10000, 1000, 300, 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, and 0.01 nM; 24 hours) exhibited significant PARP1 degradation activity, with IC50 values of 1.26, 6.72, and 0.509 nM, respectively[1]. |
| In vivo | In male BALB/c nude mice bearing xenograft Capan-1 tumors, SK-575 (25 mg/kg, 50 mg/kg; intraperitoneal injection, once daily for 5 consecutive days) inhibited tumor growth. These doses of SK-575 (25 and 50 mg/kg) were well tolerated, with no observed mouse lethality or significant weight loss during the treatment period[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (91.22 mM), Sonication is recommended.
|
| Keywords | SK-575 | SK575 | SK 575 | PARP1 |
| Inhibitors Related | BGP-15 | Niraparib tosylate monohyrate | 7-Methylguanine | Bavdegalutamide | 3-Aminobenzamide | Niraparib | AZ9482 | RMC-7977 | Olaparib | Benzamide | Vepdegestrant | OUL35 |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Breast Cancer Compound Library | Post-Translational Modification Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | High-Efficiency Gene Editing Small Molecule Library |